CTI BioPharma Corp (NASDAQ:CTIC) major shareholder Bvf Partners L. P/Il bought 5,634,108 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $16,902,324.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of CTI BioPharma Corp (NASDAQ CTIC) traded up $0.11 during trading hours on Monday, hitting $3.32. 633,711 shares of the stock were exchanged, compared to its average volume of 424,768. The company has a market cap of $142.65, a price-to-earnings ratio of -3.22 and a beta of 0.50. CTI BioPharma Corp has a 1 year low of $2.45 and a 1 year high of $4.90. The company has a quick ratio of 2.17, a current ratio of 2.19 and a debt-to-equity ratio of 0.26.
Separately, Zacks Investment Research raised shares of CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Wednesday, December 27th.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/12/cti-biopharma-corp-ctic-major-shareholder-bvf-partners-l-p-il-acquires-5634108-shares.html.
CTI BioPharma Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.